"The field of pharmaceutical innovation is an industry of strategic significance, and it is closely related to people's livelihood. There are great prospects for the field of pharmaceutical innovation in China," Ding Lieming, a member of the National Committee of the Chinese People's Political Consultative Conference, Deputy Chairman of the Zhejiang Provincial Committee of the Chinese Peasants and Workers Democratic Party, and Chairman and CEO of Betta Pharmaceuticals Co., Ltd., once again emphasized the importance of "pharmaceutical innovation" in an interview with reporters on the eve of the National Two Sessions.
Having been engaged in new drug research and development for many years, Ding Lieming has established a leading R&D and industrialization platform for tumor molecular targeted drugs in China, filling many gaps in drug research and development. He said that every step from the laboratory to clinical application requires the joint effort of policies, capital, and the industry to "break the ice."
"Many people have watched the movie 'Dying to Survive,' which depicts the reality that some cancer patients cannot afford the drugs," Ding Lieming said. In recent years, through independent innovation, China has continuously made progress in pharmaceutical innovation. And with more and more "life-saving drugs" with sky-high prices being included in the medical insurance, the economic burden on the people has been greatly reduced.
At last year's National Two Sessions, the term "innovative drugs" was written into the Government Work Report. Focusing on the future of pharmaceutical innovation, in Ding Lieming's view, there is still a bumpy road ahead.
"On the one hand, currently, the role of enterprises as the main body of innovation has not been fully exerted. Some enterprises still need to be strengthened in terms of innovation investment, tackling key core technologies, and transforming achievements. On the other hand, enterprises are faced with the practical problems of high costs, high risks, and long cycles during the innovation process, and there is an urgent need for more complete policy guidance, financial support, and optimization of the industrial environment," he said.
"The new breast cancer drug independently developed by us has entered the 'countdown' for approval, but many of our peers have fallen before the dawn due to the rupture of the capital chain," Ding Lieming said. It is necessary to make capital willing to "accompany" long-term innovation.
How can we better play the leading role of enterprises in pharmaceutical scientific and technological innovation? Ding Lieming proposed that the price formation mechanism for innovative drugs should be improved, coordinated innovation in cutting-edge fields such as stem cell therapy should be specially supported, the cooperation between government guidance funds and industrial investment funds should be enhanced, and joint efforts should be made to support the development of innovative drugs.
"In December last year, our company's Ensartinib Hydrochloride was approved for marketing in the United States, becoming the first small-molecule targeted drug for lung cancer globally launched under the leadership of a Chinese enterprise," Ding Lieming introduced. The company's achievements in coordinated innovation, the stem cell therapy for diabetes project and the plant-derived recombinant albumin project, have also made breakthroughs. In his opinion, as a highland of private economy, Zhejiang is fully capable of creating a "showroom" for the transformation of scientific and technological achievements.
Ding Lieming said that pharmaceutical innovation is not only the responsibility of scientists but also a common cause of the whole society.
Regarding the future of pharmaceutical innovation in China, Ding Lieming is full of confidence: "When policies, capital, and talents form a'snowballing' effect, we can definitely let the world witness the pharmaceutical power of 'Made in China.' We should give full play to the leading role of private enterprises in innovation and make due contributions to the development of the national pharmaceutical innovation industry and the well-being of the people."
Edit：Yao jue Responsible editor：Xie Tunan
Source：CNS.cn
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
